LONDON — For months, European countries have seesawed between craving and rebuffing AstraZeneca’s vaccine, with the shot’s fortunes rising and falling on spats over supply and on questions over the efficacy of the vaccine itself.
But few concerns have proved as disruptive to the rollout of the world’s workhorse vaccine in Europe as reports of very rare blood clots in some recipients. Many countries responded by halting the shot’s use, only to start giving it again after an all-clear from regulators at the European Medicines Agency, and then stopped inoculations a second time in certain age groups after doctors became more concerned about the clots.
On Tuesday, those concerns were reinforced yet again when a top vaccines official at the European Medicines Agency said that the vaccine was linked to extremely rare, though sometimes fatal, blood clots in a small number of recipients. It was the first indication from an international regulatory body that the clots may be a real, if very unusual, side effect of the shot.
Regulators now appear to be considering issuing their first formal warnings about the potential side effects — not only in continental Europe, which has long been wary of the shot for political and scientific reasons, but also in Britain, the birthplace of the AstraZeneca vaccine and long its biggest champion, where new data have sown concerns as well.
speedy inoculation program, have also insisted that the vaccine’s benefits far outweighed the risks. They and the company cited a lack of evidence in Britain that the clotting events were any more common than would be expected among people who had never been given AstraZeneca’s vaccine.
But the evidence changed last week when Britain reported 30 cases of the rare blood clots, 25 more than previously. This week, a prominent scientific adviser to the British government said there was “increasing evidence” of the clots being associated with the vaccine.
regulators reported 30 cases of the rare blood clots combined with low platelets among 18 million people given the AstraZeneca vaccine. That translated to roughly one case in 600,000 recipients of the vaccine.
European countries’ divergent approaches to the vaccine stem from a number of factors, including the supply of vaccines and severity of the pandemic. Marco Cavaleri, the official at the European Medicines Agency who spoke about the link between the vaccine and blood clots, said on Tuesday that those factors would likely continue to dictate how countries used the shot.
Beyond those factors, countries also took very different approaches to managing risk, scientists said. Countries that have continued using the shot were more focused on securing the overall health of their citizens. Others were more preoccupied with minimizing the risk to any single person.
“The attitude here is more, ‘Get me out of the pandemic,’” said Penny Ward, a visiting professor in pharmaceutical medicine at King’s College London, referring to the British approach. In continental Europe, she said, “There seems to be a much higher emphasis on individual safety in the population.”
Adriano Mannino, a philosopher at the University of Munich and director of the Solon Center for Policy Innovation in Germany, said that the collective benefits of the vaccine dominated thinking in Britain, while Germans were more concerned with the risk of an injection going wrong in individual cases. That reflected, partly, Germany’s history with the Nazis, who conducted lethal experiments on people.
“In many areas where law has to regulate ethically delicate and potentially dangerous things,” he said, “the German state has tended to go for tough restrictions.”
Nevertheless, Germans over 60 — the age group still being given AstraZeneca’s vaccine — flooded hotlines to book appointments and stood in line for hours in recent days as eligibility restrictions for their age group were relaxed.
In the northeastern city of Wismar, several hundred people waited for up to five hours on Tuesday in a driving wind and mix of rain and snow to receive the shot.
“I wish there had been better weather,” Kerstin Weiss, the head of the district authority in the northeastern region, told public broadcaster NDR. “But honestly, this is a sign that people are willing to be vaccinated with AstraZeneca.”
Benjamin Mueller reported from London and Melissa Eddy from Berlin. Monika Pronczuk and Emma Bubola contributed reporting.
President Biden last week named 11 people he plans to nominate to serve on federal courts, more than any recent president this early in his term. Nine are women, three are Black women and one would become the country’s first Muslim federal judge.
I spoke to Carl Hulse, The Times’s chief Washington correspondent and the author of a book about Trump-era fights over the judiciary, about why Biden is rushing to shape the courts and how judges became so central to American politics. Our conversation has been condensed.
Ian: Donald Trump’s judicial appointments were a big part of his presidency, and now Biden seems to be making filling vacancies a priority. Why have the courts become so important?
Carl: Because the courts are deciding our political fights now. Climate change, voting rights, immigration, redistricting: Because the legislative branch is so stuck, the courts are getting to be the arbiters. They’ve been amplified as a political issue because of their increased importance in deciding big, cutting-edge issues.
put 220-some judges on there — many of them very conservative, most of them white males and some of them with very little legal experience — the Biden folks concluded they needed to get different kinds of people on the courts.
The U.S. Court of Appeals for the Seventh Circuit, in Chicago, has a totally white lineup of judges. So Biden picked Candace Jackson-Akiwumi, who is a Black woman and a former federal public defender. Public defenders see the federal courts from another side — from the perspective of the defendant. That’s a big change. I think Biden wanted to make a statement about the kinds of judges he wants: people with different life and legal experiences.
There are currently 68 vacancies, with another 26 scheduled to open this year. Does that limit how transformative Biden can be?
The transformation is going to be in the types of judges. Biden is going to have a hard time matching Trump’s numbers, which were over four years. And that was a concerted campaign by Mitch McConnell, to the exclusion of many other things.
a bigger point of emphasis because of Trump. Democrats watched what Senator McConnell did so successfully, and they are eager to replicate that from the other end of the ideological spectrum. Trump’s going to have people on the bench for 30 years, maybe 40. There’s still a few Reagan judges out there.
Trump appointed three justices to the Supreme Court. Many Democrats hope that Stephen Breyer, who is 82 and one of the court’s three remaining liberals, will retire soon. Does that seem like Biden’s best hope to fill a seat?
We’ll see what happens. A lot of Democrats don’t want to get caught in this Ruth Bader Ginsburg situation again. And Justice Breyer is an extremely smart guy, and also a political guy. He knows what’s going on here.
THE LATEST NEWS
Suzanne Nossel argues in Foreign Policy.
“A lot of them wanted to blow up Washington. That’s why they thought they were elected,” John Boehner, a Republican who served as House speaker, writes in Politico Magazine about the right’s paranoid turn. (Warning: Profanity abounds.)
A New SoHo: It was a haven for artists. Now it’s full of luxury storefronts. What’s next? Maybe affordable housing.
Lives Lived: Winfred Rembert survived a near-lynching in rural Georgia in 1967. He learned to carve figures into leather while in prison, and later became a renowned artist whose work told the story of the Jim Crow South. He died at 75.
writes in The Times.
The pandemic has left many reeling from a loss of health, of income, of loved ones or of a normal way of life. Though circumstances vary, the mood is often similar.
“When people are under a long period of chronic, unpredictable stress, they develop behavioral anhedonia” — a reduced ability to take pleasure in activities — Margaret Wehrenberg, an expert on anxiety, said. “And so they get lethargic, and they show a lack of interest — and obviously that plays a huge role in productivity.”
How are people trying to cope? Some are meditating, turning to alcohol or edibles, going for walks or re-engaging with a spiritual practice. Others are finding pockets of joy where they can — sending postcards, exchanging gifts with neighbors or adopting pets. And some have embraced the notion that it’s all right not to be productive during a period of major global upheaval.
“You’re supposed to be inventing something or coming up with the next big business idea,” one person told The Times last year. “I’m trying to be more OK with just being.”
What to Watch
The Korean star Yuh-Jung Youn has had a thriving career for five decades. Now, at 73, she’s up for an Oscar for her role in “Minari.” She spoke with The Times about her career.
Explore the hidden details of this stunning 17th-century portrait of the emperor who built the Taj Mahal.
Daniel Kaluuya, star of “Get Out” and “Judas and the Black Messiah,” hosted “Saturday Night Live” this past weekend. Here’s a recap.
Now Time to Play
And Friday’s Bee Plus answer: CHINA, CHIA, ECHINACEA
Here’s today’s Mini Crossword, and a clue: Gas that comes down as rain on Jupiter (four letters).